Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Myriad Genetics, Inc.
< Previous
1
2
Next >
Myriad Genetics Earns 2024 Great Place To Work® Certification™
July 02, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
June 24, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
June 11, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
June 04, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
June 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
May 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
QGEN
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
May 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
May 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
May 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
April 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
April 17, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
April 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
April 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
March 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
March 20, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
February 27, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 27, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
February 15, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
February 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
January 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
January 18, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
January 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
December 21, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
December 20, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
November 20, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
November 16, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Participate in Stephens Annual Investment Conference
November 09, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.